• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>TheraSense

TheraSense

  1. Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients

    Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.